Sometimes, what goes up must come down.
News & Analysis: GTx
The company's only drug candidate failed a mid-stage clinical trial. The next clinic-ready assets are on the way -- in late 2019 or early 2020.
Find out how these stocks lifted the market.
These five companies posted double-digit percentage declines this past week.
After a history of failures, these three biotech stocks are running out of ideas and cash to keep their operations going.
These stocks suffered double-digit percentage declines last week.
An FDA approval, exciting early-stage pancreatic cancer data, the revival of a drug that will not go quietly into the night, and a biotech implosion on disappointing study data are this week's top stories.
GTx collapsed 65% after a failed phase 3 drug trial.
While Mr. Market gave high fives to lots of investors this week, these health-care stocks got nothing but two thumbs down.
Phase III trial data should begin arriving this summer.